Patients treated with pirfenidone | Patients never treated with pirfenidone | |||||
---|---|---|---|---|---|---|
Total (n = 142) | Autoantibody ( −) (n = 93) | Autoantibody ( +) (n = 49) | Total (n = 92) | Autoantibody ( −) (n = 57) | Autoantibody ( +) (n = 35) | |
Sex (male) | 110 (77.5%) | 71 (76.3%) | 39 (79.6%) | 64 (69.6%) | 40 (70.2%) | 724(68.6%) |
Age (year) | 69.5 ± 7.3 | 70.0 ± 6.8 | 68.5 ± 8.0 | 67.1 ± 10.3 | 67.1 ± 11.2 | 67.0 ± 8.7 |
BMI (kg/m2) | 24.8 ± 2.9 | 25.2 ± 3.0 | 24.0 ± 2.7 | 23.3 ± 3.0 | 23.2 ± 3.2 | 23.5 ± 2.6 |
Smoking exposure (%) | ||||||
Never | 43 (30.3%) | 32 (34.4%) | 11 (22.4%) | 7 (7.6%) | 4 (7.0%) | 3 (8.6%) |
Former | 80 (56.3%) | 50 (53.8%) | 30 (61.2%) | 51 (55.4%) | 34 (59.6%) | 17 (48.6%) |
Current | 19 (13.4%) | 11 (11.8%) | 8 (16.3%) | 34 (37.0%) | 19 (33.3%) | 15 (42.9%) |
Smoking (pack-years) | 20.0 (0.0–40.0) | 20.0 (0.0–36.0) | 30.0 (6.0–45.0) | 15.0 (0.0–32.5) | 20.0 (0.0–35.0) | 4.2 (0.0–30.0) |
Comorbidities | ||||||
Hypertension | 30 (21.1%) | 23 (24.7%) | 7 (14.3%) | 44 (47.8%) | 28 (49.1%) | 16 (45.7%) |
Diabetes mellitus | 38 (26.8%) | 30 (32.3%) | 8 (16.3%) | 24 (26.1%) | 19 (33.3%) | 5 (14.3%) |
GERD | 46 (32.4%) | 30 (32.3%) | 16 (32.7%) | 27 (29.3%) | 19 (33.3%) | 8 (22.9%) |
Asthma | 11 (7.7%) | 9 (9.7%) | 2 (4.1%) | 5 (5.4%) | 3 (5.3%) | 2 (5.7%) |
Old pulmonary tuberculosis | 28 (19.7%) | 19 (20.4%) | 9 (18.4%) | 18 (19.6%) | 13 (22.8%) | 5 (14.3%) |
Cancer | 29 (20.4%) | 18 (19.4%) | 11 (22.4%) | 23 (25.0%) | 17 (29.8%) | 6 (17.1%) |
Coronary artery disease | 25 (19.6%) | 14 (15.1%) | 11 (22.4%) | 19 (20.7%) | 11 (19.3%) | 8 (22.9%) |
Cerebrovascular disease | 4 (2.8%) | 4 (4.3%) | 0 (0.0%) | 5 (5.4%) | 5 (8.8%) | 0 (0.0%) |
Pulmonary function test (at IPF diagnosis) | ||||||
FVC (L) | 2.6 ± 0.7 | 2.7 ± 0.7 | 2.6 ± 0.6 | 2.8 ± 0.9 | 2.8 ± 0.9 | 2.8 ± 0.8 |
FVC % pred | 77.0 ± 13.0 | 78.2 ± 13.9 | 74.7 ± 10.8 | 83.6 ± 20.0 | 81.8 ± 20.6 | 86.5 ± 18.8 |
FEV1 (L) | 2.1 ± 0.5 | 2.1 ± 0.5 | 2.1 ± 0.4 | 2.2 ± 0.7 | 2.2 ± 0.7 | 2.2 ± 0.6 |
FEV1% pred | 90.7 ± 15.0 | 91.5 ± 14.8 | 89.3 ± 15.4 | 96.2 ± 22.6 | 94.5 ± 23.5 | 99.1 ± 21.1 |
DLCO (mL/mmHg/min) | 10.8 (8.7–13.2) | 11.1 (8.7–13.6) | 9.8 (8.6–12.0) | 13.0 ± 4.6 | 13.4 ± 4.6 | 12.2 ± 4.5 |
DLCO % pred | 63.0 (53.0–73.0) | 65.0 (55.0–76.0) | 60.0 (52.0–72.0) | 70.5 ± 24.4 | 72.9 ± 25.9 | 66.7 ± 21.6 |
Obstructive pattern | 8 (5.6%) | 5 (5.4%) | 3 (6.1%) | 7 (7.6%) | 5 (8.8%) | 2 (5.7%) |
Severity of IPF (GAP index) | ||||||
I | 126 (88.7%) | 81 (87.1%) | 45 (91.8%) | 48 (84.2%) | 48 (84.2%) | 32 (91.4%) |
II | 16 (11.3%) | 12 (12.9%) | 4 (8.2%) | 9 (15.8%) | 9 (15.8%) | 3 (8.6%) |
Follow-up period (months) | 24.4 (14.9–32.7) | 24.4 (16.6–32.2) | 24.2 (11.7–32.7) | 31.1 (12.6–54.8) | 28.7 (13.8–52.7) | 40.3 (12.3–56.0) |
Acute exacerbation | 26 (18.3%) | 20 (21.5%) | 6 (12.2%) | 13 (14.1%) | 10 (17.5%) | 3 (8.6%) |
Pirfenidone dose (mg) | 1184.5 (837.3–1467.3) | 1185.6 (890.7–1398.0) | 1183.5 (836.0–1550.2) | – | – | – |
CT scan patterna | ||||||
UIP | 124 (87.3%) | 86 (92.5%) | 38 (77.6%) | 76 (82.6%) | 48 (84.2%) | 28 (80.0%) |
Possible UIP | 18 (12.7%) | 7 (7.5%) | 11 (22.4%) | 16 (17.4%) | 9 (15.8%) | 7 (20.0%) |
UIP by surgical lung biopsy | 44 (31.0%) | 26 (28.0%) | 18 (36.7%) | 30 (32.6%) | 18 (31.6%) | 12 (34.3%) |